Pretreated EGFRdel19/BRAFV600E Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report.

Orciuolo, Corrado; Cappuzzo, Federico; Landi, Lorenza; Resuli, Blerina; Carpano, Silvia; Vidiri, Antonello; Buglioni, Simonetta; Mandoj, Chiara; Ciliberto, Gennaro; Minuti, Gabriele

Pretreated EGFR^del19/BRAF^V600E Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report.

Orciuolo, Corrado; Cappuzzo, Federico; Landi, Lorenza; Resuli, Blerina; Carpano, Silvia; Vidiri, Antonello; Buglioni, Simonetta; Mandoj, Chiara; Ciliberto, Gennaro; Minuti, Gabriele.

Afiliação

Orciuolo C; Division of Medical Oncology 2, IRCCS National Cancer Institute Regina Elena, Rome, Italy.
Cappuzzo F; Division of Medical Oncology 2, IRCCS National Cancer Institute Regina Elena, Rome, Italy.
Landi L; Clinical Trials Center: Phase 1 and Precision Medicine, IRCCS National Cancer Institute Regina Elena, Rome, Italy.
Resuli B; Division of Medical Oncology 2, IRCCS National Cancer Institute Regina Elena, Rome, Italy.
Carpano S; Division of Medical Oncology 2, IRCCS National Cancer Institute Regina Elena, Rome, Italy.
Vidiri A; IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Buglioni S; IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Mandoj C; IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Ciliberto G; IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Minuti G; Clinical Trials Center: Phase 1 and Precision Medicine, IRCCS National Cancer Institute Regina Elena, Rome, Italy.

JTO Clin Res Rep ; 4(8): 100545, 2023 Aug.

Article em En | MEDLINE | ID: mdl-37533438

RESUMO

Oncogene-addicted NSCLC inevitably becomes resistant to targeted therapy by developing acquired resistance through on- or off-target mechanisms, potentially detectable by liquid biopsy. We present the first reported case of a patient with pretreated EGFRdel19/BRAFV600E lung adenocarcinoma and symptomatic leptomeningeal metastasis obtaining durable clinical benefit on osimertinib, dabrafenib, and trametinib treatment.

Palavras-chave

Case report; NSCLC; Osimertinib; Resistance; Targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links